Skip to main content
. 2022 Jul 28;16:899772. doi: 10.3389/fnins.2022.899772

FIGURE 4.

FIGURE 4

Distribution of the reported adverse effects by both groups on the Discontinuation-Emergent Sign and Symptom inventory.